DAY 3

Japan's basic research in regenerative medicine, including iPS cells, is world-class, but it has been difficult to commercialize and put it into practical use. To overcome challenges such as complex regulations and approvals, insurance coverage and pricing, and seamless collaboration between universities and research institutions, a three-pronged strategy involving policy, industry, and research is essential. Meanwhile, overseas, aggressive investment and regulatory relaxation are accelerating development.Does Japan have a competitive edge in iPS-based drug development and regenerative medicine? In Kyoto, a hub of cutting-edge medical technology, experts from various fields will discuss challenges and potential solutions that apply to drug development as a whole.